Stocks and Investing
Stocks and Investing
Tue, May 16, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ed Arce Maintained (AKRO) at Strong Buy with Decreased Target to $62 on, May 16th, 2023
Ed Arce of HC Wainwright & Co., Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Decreased Target from $64 to $62 on, May 16th, 2023.
Ed has made no other calls on AKRO in the last 4 months.
There are 2 other peers that have a rating on AKRO. Out of the 2 peers that are also analyzing AKRO, 0 agree with Ed's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Ed
- Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $58 on, Tuesday, March 21st, 2023
- Michael Ulz of "Morgan Stanley" Upgraded from Hold to Buy and Held Target at $65 on, Friday, January 27th, 2023
Contributing Sources